Diaceutics PLC (DXRX) fair value: what the stock is really worth
We calculate from audited financials what Diaceutics PLC is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Structural break:
The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Stretched ValuationStrong overvaluation with only moderate quality.
!Fair value £0.2600 · Strongly overvalued (−84%)
✓Quality 72/100
!Mixed Growth(revenue 5y +24.8 %/yr)
!Thin margins · 0.3% net margin (TTM)
✓Low debt · generates free cash flow
!Trails peers(4/12)
!Narrow moat34/100
!Evidence only medium, so the estimate is less certain
Watch Diaceutics PLC for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range £0.7450 – £1.77 · the £1.58 price screens above the £0.2600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories.
Show more
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, which delivers an actionable alert of a testing behavior for making treatment decisions; DXRX Physician Mapping that examines physician testing behavior using patient level data to determine testing rates, methodology, and physician to lab relationship; DXRX Lab Mapping that offers insights into labs currently testing patients diagnosed with a specific disease or biomarker; and DXRX Disease Testing Rate Tracker, which delivers biomarker testing rate reports. In addition, the company offers professional services, such as market landscape, implementation, and consulting services. It operates in North America, the United Kingdom, Europe, Asia, and internationally. The company was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.
Stock analysis
Diaceutics PLC (DXRX) currently trades at £1.58, while our model-based Fair Value estimate is £0.2600, implying the stock looks roughly 507.5% overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of £0.3800 per share, and 1 of the 23 models we run sit above the £1.58 price.
Bear case: the Earnings-Based group reads lowest at £0.0300, and 22 of the 23 models stay below the price. Evidence for this calculation is medium.
Quality & growth
The Quality Score stands at 72/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Diaceutics PLC reported revenue of £38.4M in FY2025 versus £13.9M in FY2021, a compound +28.9%/yr. Reported net income was £97.0K in FY2025, compounding −35.5%/yr from FY2021.
Key figures
Market cap 134M GBX · P/S ratio 2.97 · Dividend yield 0.2% · Net margin 0.3% · Return on equity 0.2% · Return on assets (EBIT) −1.9% · Operating margin 13.5% · Revenue (TTM) £38.4M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at −42% fair-value upside, at −84%, DXRX screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (£0.0200 to £1.59). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear £0.2600Fair Value £0.2600Bull £0.2600
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+19.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.8%
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.3%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−28.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−28.7%
Dividend (yield on the price)0.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−29% vs −20%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−5% → −1%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 129 stocks
Beats the industry median on 3/11 measures
Overall it trails its industry peers.
Valuation
Quality Score72 · Top 25%
Profitability
Return on equity (TTM)0% · Below median
Return on assets0% · Below median
Net margin (TTM)0% · Below median
Operating margin (TTM)14% · Top 25%
Growth and dividend
Revenue growth20% · Above median
Dividend yield (TTM)0.2% · Bottom 25%
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/B3.82× · Pricier than median
P/S (TTM)4.02× · Pricier than median
P/FCF108.4× · Priciest 25%
EV/EBITDA36.0× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 33
PAST (return on equity)1· sector 6
HEALTH (low debt)100· sector 98
DIVIDEND (yield)0· sector 47
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Diaceutics PLC Fair Value". https://www.fairvalue-calculator.com/stock/DXRX
Frequently asked questions
Is Diaceutics PLC (DXRX) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of £0.2600 versus a price of £1.58, about −84% upside (overvalued).
What is the fair value of DXRX?
Our model-based fair value for Diaceutics PLC is £0.2600 (as of Sep 13, 2026), built from audited fundamentals. The current price: £1.58.
What is the quality score of DXRX?
Diaceutics PLC has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Diaceutics PLC (DXRX)?
Our model-based price target is the fair value of £0.2600 (as of Sep 13, 2026) from 23 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Diaceutics PLC stock forecast for 2026?
Our models put fair value at £0.2600, about −84% upside versus a price of £1.58 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Diaceutics PLC (DXRX)?
Diaceutics PLC reported trailing-twelve-month revenue of about £38.4M (latest available figure, as of Sep 13, 2026).
Does Diaceutics PLC pay a dividend?
Diaceutics PLC currently shows a dividend yield of about 0.16% relative to its recent price (as of Sep 13, 2026).
What is the intrinsic value of Diaceutics PLC (DXRX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Diaceutics PLC it is £0.2600 per share (as of Sep 13, 2026), against a price of £1.58. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Diaceutics PLC stock overvalued or undervalued in 2026?
As of Sep 13, 2026, DXRX trades above its calculated fair value: price £1.58, fair value £0.2600, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DXRX?
No. The price is what the market pays today (£1.58); the fair value is what the company's own numbers justify (£0.2600). For Diaceutics PLC the two are £1.32 per share apart. That gap is exactly why we show both numbers side by side.
How much is Diaceutics PLC worth?
The market values Diaceutics PLC at about 134M GBX (market capitalisation, as of Sep 13, 2026). Per share that is £1.58; our models calculate a fair value of £0.2600 per share.
How solid is the balance sheet of Diaceutics PLC (DXRX)?
Balance-sheet figures for Diaceutics PLC (as of Sep 13, 2026): return on equity 0.2%. They feed the Quality Score of 72/100, which measures business quality independently of the share price.
Which stocks are comparable to Diaceutics PLC?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, HealthEquity, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Diaceutics PLC stock attractive at the current price?
The data as of Sep 13, 2026: price £1.58, calculated fair value £0.2600 (−84%), Quality Score 72/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DXRX calculated?
We run Diaceutics PLC through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of £0.2600, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Diaceutics PLC itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Diaceutics PLC right now?
A high-quality business (quality 72/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (£0.2600). The favourable scenario is already priced in.
Key figures of Diaceutics PLC
How large is the market capitalisation of Diaceutics PLC (DXRX)?
The market capitalisation of Diaceutics PLC is 134M GBX. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Diaceutics PLC (DXRX)?
The price-to-sales ratio of Diaceutics PLC is 2.97 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Diaceutics PLC (DXRX)?
The dividend yield of Diaceutics PLC is 0.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Diaceutics PLC (DXRX)?
The net margin of Diaceutics PLC is 0.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Diaceutics PLC (DXRX)?
The return on equity (ROE) of Diaceutics PLC is 0.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Diaceutics PLC (DXRX)?
On an EBIT basis the return on assets of Diaceutics PLC is −1.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Diaceutics PLC (DXRX)?
The operating margin of Diaceutics PLC is 13.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Diaceutics PLC (DXRX)?
Revenue at Diaceutics PLC is growing +20.3% versus a year earlier (3y avg +25.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Diaceutics PLC (DXRX)?
Earnings per share at Diaceutics PLC are growing +180% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Diaceutics PLC (DXRX) generate?
The free cash flow of Diaceutics PLC is £1.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Diaceutics PLC (DXRX) hold?
Diaceutics PLC holds more cash than debt, £6.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Diaceutics PLC in the live analysis
One click puts Diaceutics PLC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
